Member Info for Canis

Watched a recording of AGM - I was unimpressed because just the same old BS about developing their pipeline and expect to give more news flow in coming period. Strong financial standing which probably means another cash raise in next 6 months. I’m looking for an exit plan like many here!

Bioglucagon - treatment for hypoglycaemia

Was there a time scale for other products in pipeline - diabetes “pen” which was supposed to be almost ready and seeking partners to market. It’s about time they started making some money! Excuse me but just can’t recall it’s name.

It is a very true saying - BS baffles brains.
It’s time for plain speaking from investor relations!

Investor relations person - Lisa Baderoon doesn’t normally answer your questions by email. Instead she will invite you to telephone. I think she isn’t keen on committing to print for some reason. In any case she will not answer any of your question - just fob you off!

Following further clinical submissions from Immupharma & Avion there is to be a decision on second Phase III trial by FDA by 30th June 2021. If a second Phase III not granted there's not much hope - only hope would be that some big pharma thinks patents worth giving a few pence a share for! Immupharma won't survive on Incanthera or Eureka hype.

Mav,
I mostly use BB's to observe.

Bojo,

I can only refer you to Immupharma website - Through their subsidiary Ureka Pharma who is partner in a consortium developing peptides intended to block Covid -19 & other viruses from attaching to target cells - using Ureka patented Tech together with contributions from other members of consortium.
This is AIM and therefore it takes very little to influence SP sometimes!

Because of their link to covid - using IMM peptide technology. Pfizer now have jump on everyone!

Does anyone on here work for a living - seems to me lots of time on your hands - I'm only envious!
I'm holding 493k of these - highest price paid 173p prior to phase 3 readout. Spent last couple of years averaging down to 17p. Lost interest in these cos Tim is full of BS!

Although deal with Lanstead was done towards end of June and they received their shares beginning of July Lansteads payments to IMM only commenced beginning of Sept, so only 4 payments in total so far!

The Managed Access Program which had been due to commence earlier in the year - then halted most likely due to negotiations with potential partners - is it possible that people recruited for this would now participate in the new phase III trial therefore accelerating the timetable to new phase III results?

I'm polishing my balls - turned down a 24K profit this morning at 32p - cos I think there's more upward movement to come.

Don't get carried away! Life Sciences Division gave this a target of 76p just a couple of months ago with this deal in mind.

Immupharma have stated that they wouldn't fund a further phase III themselves - therefore they're actively seeking a partner. The most recent RNS states that discussions with regulatory bodies were underway regarding the design of a new phase III trial. Hopefully a partnership announcement will be made soon!

Ureka / Immupharma and University of Bordeaux now published: Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking - published in Chemical Science. https://pubs.rsc.org/en/content/articlelanding/2019/sc/c9sc02079a#!divAbstract

Lanstead's payments start 1st Sept' - the amount is dependent on an average of SP during 20 days prior to payment day. We are in that zone now therefore most likely to see an RNS to help raise the average price!
Come on Tim, open the doors to that rich vein of positive news flow you spoke about early July.

No-one gets the rationale behind the Incanthera investment - especially after this recent fund raise. The company alleges that they didn't need to raise funds just now!! Tim stated that with the money leftover from trial expenses at end of 2018 (4.9 million) and this new money puts them in a very strong financial position.
Anyone know what monthly cashburn might be - we don't know how much of the 4.9 million is left six months on. It's all a bit vague.

It's at an all time low, however this could be the time to buy! At least for the short term.
I don't know Tim McCarthy but I think he has been the focus for much understandable frustrations, just bear in mind there is a BOD making the decisions, some of which recently have been like ****ing in your own nest!
Nolupus, you have been the realist here and I hold your comments in high regard, however I don't agree with your statement on Lanstead that they are in a win win situation. I watched the recent video on Proactive Investors explaining the mechanics of the Lanstead deal and although the money they pay to Immupharma is relative to the share price they have already received all of their shares and are a major share holder. It is in their interest for the share price to improve.
It is imperative for Immupharma that the share price improves from here to benefit substantially from this deal and in said video TM stated that both companies would not have entered an agreement unless there would be positive news flow to improve share price - that needs to be within the next two months because the Lanstead payments kick-in thereafter and they are dependent on share price. A further phase III trial would need to be successful to gain regulatory approval - to which Tim alluded would not be paid for by Immupharma, therefore it is possible a partnership deal is in final discussions because this is the only piece of news IMHO which could move the share price substantially.

Whilst negotiating the subscription deal I'm assuming Lanstead had access to information we PI's aren't privy to - why else would they invest 2.66 million?
The amount of monies payable to immupharma through the subscription is dependent on the share price being higher or lower than a base price of 13.33p. The payments are due to commence in a couple of months, therefore I'm expecting positive news flow from Immupharma over the next few weeks in order to maintain and improve share price otherwise the subscription payments will be lower than anticipated.